Bloomberg Morning Report

July 31 (Bloomberg) -- Jane King summarizes the top stories this morning on the Bloomberg Business Report. (Source: Bloomberg)

Merck KgaA, Pfizer Cancer Drug to Cost $13,000 a Month
04:03 - Pfizer and Merck KGaA’s cancer immunotherapy won approval from U.S. regulators for patients with a rare form of skin cancer, and the companies plan to sell the drug for $13,000 a month. Merck KgaA CEO Stegfan Oschmann speaks on "Bloomberg Daybreak Europe." (Source: Bloomberg)
  • Aviva's Diebel Sees No Macro Impact From Healthcare Bill
  • Italy Junior Minister Sees Brexit as EU Opportunity
  • French Presidential Race Takes an Inflammatory Turn